Paper3603036
Delay time of hemoglobin S polymerization prevents most cells from sickling in vivo.
Mozzarelli A and 2 others. Science, 1987. Cited by 178 papers, by iCite.
Cite this record
ConductScience Library. Delay time of hemoglobin S polymerization prevents most cells from sickling in vivo. Papers, record 3603036. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/3603036
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics14
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Anemia, Sickle Cell | Major topic |
| Erythrocytes, Abnormal | Major topic |
| Hemoglobin, Sickle | Major topic |
| Biopolymers | |
| Carbon Monoxide | |
| Gels | |
| Humans | |
| Kinetics | |
| Lasers | |
| Light | |
| Oxygen | |
| Photolysis | |
| Scattering, Radiation | |
| Spectrophotometry |
Source PubMed
Cited by77
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 178 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42721489 | Endothelin receptor antagonism in sickle cell disease: Is the time now? | Can J Physiol Pharmacol | 2026 | https://conductscience.org/library/papers/42721489 | PubMed |
| 42652065 | Oxygen Timing as Therapy: Molecular Rationale and Clinical Imperative for Early Oxygen Administration in the Sickle Cell Disease Vaso-Occlusive Crisis-A Structured Narrative Review with Implications for Resource-Constrained Health Systems. | Biomedicines | 2026 | https://conductscience.org/library/papers/42652065 | PubMed |
| 42088340 | Two birds with one stone: An antibiotic hit blocking Staphylococcus aureus heme uptake with serendipitous hemoglobin left-shifting activity. | iScience | 2026 | https://conductscience.org/library/papers/42088340 | PubMed |
| 41630670 | Microfluidic capillary transit velocity as a functional measure for sickle cell disease and in vitro-derived red blood cells. | Lab Chip | 2026 | https://conductscience.org/library/papers/41630670 | PubMed |
| 41628968 | Sphingosine-1-Phosphate Regulation to Alleviate Sickle Cell Disease Severity: A Promising Therapeutic Approach. | Saudi Med J | 2026 | https://conductscience.org/library/papers/41628968 | PubMed |
| 41538305 | Ferroportin inhibition attenuates pulmonary hypertension in hypoxic sickle cell disease mice. | Blood Adv | 2026 | https://conductscience.org/library/papers/41538305 | PubMed |
| 40124403 | Sticking together: Polymerization of sickle hemoglobin drives the multiscale pathophysiology of sickle cell disease. | Biophys Rev (Melville) | 2025 | https://conductscience.org/library/papers/40124403 | PubMed |
| 39056767 | Post-GWAS Validation of Target Genes Associated with HbF and HbA2 Levels. | Cells | 2024 | https://conductscience.org/library/papers/39056767 | PubMed |
| 38605818 | A framework of computer vision-enhanced microfluidic approach for automated assessment of the transient sickling kinetics in sickle red blood cells. | Front Phys | 2024 | https://conductscience.org/library/papers/38605818 | PubMed |
| 37615662 | Clinical and laboratory factors associated with splenic dysfunction among patients with sickle cell disease in a malaria endemic region. | Trans R Soc Trop Med Hyg | 2023 | https://conductscience.org/library/papers/37615662 | PubMed |
| 37270670 | Voxelotor does not inhibit sickle hemoglobin fiber formation upon complete deoxygenation. | Biophys J | 2023 | https://conductscience.org/library/papers/37270670 | PubMed |
| 36406833 | Intravenous Fluid Administration and the Risk of Adverse Outcomes in Sickle Cell Disease Patients Hospitalized for Vaso-Occlusive Crisis. | J Hematol | 2022 | https://conductscience.org/library/papers/36406833 | PubMed |
| 36406264 | Drug discovery by a basic research scientist. | Front Mol Biosci | 2022 | https://conductscience.org/library/papers/36406264 | PubMed |
| 36161945 | Phenotypic screening of the ReFRAME drug repurposing library to discover new drugs for treating sickle cell disease. | Proc Natl Acad Sci U S A | 2022 | https://conductscience.org/library/papers/36161945 | PubMed |
| 36134985 | Extracellular Vesicles in Sickle Cell Disease: A Promising Tool. | Bioengineering (Basel) | 2022 | https://conductscience.org/library/papers/36134985 | PubMed |
| 35714304 | The oral ferroportin inhibitor vamifeport improves hemodynamics in a mouse model of sickle cell disease. | Blood | 2022 | https://conductscience.org/library/papers/35714304 | PubMed |
| 35366607 | Mitapivat increases ATP and decreases oxidative stress and erythrocyte mitochondria retention in a SCD mouse model. | Blood Cells Mol Dis | 2022 | https://conductscience.org/library/papers/35366607 | PubMed |
| 34765367 | A Patient With Hemoglobin SC Disease and Acute Ischemic Stroke Presenting With Altered Mental Status. | Cureus | 2021 | https://conductscience.org/library/papers/34765367 | PubMed |
| 34490315 | Extracellular Vesicles in Sickle Cell Disease: Plasma Concentration, Blood Cell Types Origin Distribution and Biological Properties. | Front Med (Lausanne) | 2021 | https://conductscience.org/library/papers/34490315 | PubMed |
| 34274158 | Impact of hemoglobin biophysical studies on molecular pathogenesis and drug therapy for sickle cell disease. | Mol Aspects Med | 2022 | https://conductscience.org/library/papers/34274158 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/3603036
GET https://conductscience.org/api/papers/v1/3603036/cited_by?page=2